Avalo Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Avalo Therapeutics, Inc. carries a market capitalization of 1.01B, placing it among publicly traded companies globally. Its enterprise value stands at 577.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.01B |
| Enterprise Value | 577.57M |
Share Statistics
Avalo Therapeutics, Inc. currently has 52.90M shares outstanding.
| Shares Outstanding | 52.90M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 8,113.39, and the price-to-book ratio stands at 2.18.
| PE Ratio | N/A |
| PS Ratio | 8,113.39 |
| PB Ratio | 2.18 |
| P/TBV Ratio | 2.23 |
| P/FCF Ratio | -7.01 |
| P/OCF Ratio | -7.01 |
Enterprise Valuation
| EV / Sales | 9,789.34 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Avalo Therapeutics, Inc. maintains a current ratio of 19.31, meaning it holds 19.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 19.31 |
| Quick Ratio | 18.94 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -36.27 |
| Return on Assets (ROA) | -32.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 171,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Avalo Therapeutics, Inc.'s stock has gained approximately 65.77586% over the past 52 weeks. The 50-day moving average sits at 19.08, while the 200-day moving average is 16.91.
| Beta (5Y) | N/A |
| 52-Week Price Change | 65.77586% |
| 50-Day Moving Average | 19.08 |
| 200-Day Moving Average | 16.91 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Avalo Therapeutics, Inc. generated 59,000.00 in revenue and converted that into -100.33M in net income, yielding earnings per share of -3.87. EBITDA reached -91.25M, while operating income came in at -91.36M.
| Revenue | 59,000.00 |
| Gross Profit | 59,000.00 |
| Operating Income | -91.36M |
| Pretax Income | -100.16M |
| Net Income | -100.33M |
| EBITDA | -91.25M |
| EBIT | -91.36M |
| Earnings Per Share (EPS) | -3.87 |
Balance Sheet
Avalo Therapeutics, Inc. holds 400.28M in cash and equivalents against 242,000.00 in total debt, resulting in a net debt position of -85.38M. Total book value stands at 448.66M, with working capital of 386.80M providing operational flexibility.
| Cash & Cash Equivalents | 400.28M |
| Total Debt | 242,000.00 |
| Net Debt | -85.38M |
| Equity (Book Value) | 448.66M |
| Book Value Per Share | 8.48 |
| Working Capital | 386.80M |
Cash Flow
Avalo Therapeutics, Inc. produced -68.29M in operating cash flow over the past twelve months.
| Operating Cash Flow | -68.29M |
| Capital Expenditures | N/A |
| Free Cash Flow | -68.29M |
| FCF Per Share | -2.64 |
Margins
Avalo Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -154,844.07 and net profit margin of -170,055.93 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -154,844.07 |
| Pretax Margin | -169,766.10 |
| Profit Margin | -170,055.93 |
| EBITDA Margin | -154,659.32 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -43.64 |
| FCF Yield | -14.27 |
Stock Splits
Avalo Therapeutics, Inc.'s most recent stock split took place on December 29, 2023 with a 240:1 split ratio.
| Last Split Date | 12/29/2023 |
| Split Ratio | 240:1 |
Scores
Avalo Therapeutics, Inc. posts an Altman Z-Score of 12.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 12.79 |